Summary

KEY FINDINGS
The Asia-Pacific 3D bioprinting market is expected to register a CAGR of 16.81% during the forecast period, 2023-2032. The industrial aspects of gene therapy have garnered attention in Korea, Japan, and China, leading to the establishment of several start-ups and a lucrative environment in terms of investments. As a result, the surging demand for gene therapies indirectly boosts the demand for 3D-printed products in the region.
MARKET INSIGHTS
China, South Korea, Australia & New Zealand, Thailand, Japan, India, Singapore, and Rest of Asia-Pacific are evaluated for the Asia-Pacific 3D bioprinting market growth assessment. In India, the government promotes research & development initiatives in regenerative medicine (RM). Also, several complex interlinkages among governments, academia, and industry have facilitated the development of innovative capacity. This is evident in initiatives associated with tissue engineering, gene therapy, stem cell & cord blood banking, gene therapy, 3D bioprinting, and biomaterials.
In Singapore, researchers at the Singapore Institute of Manufacturing Technology were able to create realistic colorations on printed samples by regulating melanin production in bioink (November 2019). In August 2020, researchers from the Singapore University of Technology and Design (SUTD) demonstrated a new level of control in the directed differentiation of stem cells by means of a printed micro-scaled physical device. Moreover, the Nanyang Technological University Singapore (NTU Singapore) scientists used sunflower pollen to develop a 3D printing ink material that can be used to fabricate parts useful for drug delivery, toxicity testing, and tissue engineering. Such factors offer growth opportunities for the analyzed market in these countries.
COMPETITIVE INSIGHTS
Some of the leading companies in the market are ROKIT Healthcare Inc, Organovo Holdings Inc, GeSiM GmbH, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON 3D BIOPRINTING MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. EMERGENCE OF 4D BIOPRINTING AS A SUBSTITUTE FOR 3D BIOPRINTING
2.5.2. PERSONALIZED MEDICINE LIKELY TO BOOST 3D BIOPRINTING
2.5.3. RISING INTEREST IN THE APPLICATION OF BIOPRINTING AGAINST THE SARS-COV-2 VIRUS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. SURGING GERIATRIC POPULATION
3.1.2. TECHNOLOGICAL ADVANCEMENTS AND R&D INVESTMENTS
3.1.3. RISING FOCUS ON REGENERATIVE MEDICINE
3.1.4. HIGH PREVALENCE OF CHRONIC CONDITIONS
3.2. KEY RESTRAINTS
3.2.1. OPERATIONAL CHALLENGES DURING MANUFACTURING
3.2.2. EXORBITANT COSTS OF 3D BIOPRINTERS
3.2.3. LACK OF TRAINED PROFESSIONALS
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.4.1. GROWTH PROSPECT MAPPING IN CHINA
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. DESIGN & SOFTWARE PROVIDERS
4.7.2. PROTOTYPE PRODUCTION
4.7.3. DISTRIBUTION
4.7.4. END-USERS
5. MARKET BY COMPONENT
5.1. 3D BIOPRINTER
5.2. BIOINK
6. MARKET BY BIOMATERIAL
6.1. HYDROGEL
6.2. LIVING CELLS
6.3. EXTRACELLULAR MATRICES
6.4. OTHER BIOMATERIALS
7. MARKET BY TECHNOLOGY
7.1. MAGNETIC LEVITATION BIOPRINTING
7.2. INKJET-BASED BIOPRINTING
7.3. SYRINGE/EXTRUSION-BASED BIOPRINTING
7.4. LASER-ASSISTED BIOPRINTING
7.5. OTHER TECHNOLOGIES
8. MARKET BY APPLICATION
8.1. DRUG TESTING & DEVELOPMENT
8.2. TISSUE ENGINEERING & REGENERATIVE MEDICINE
8.3. FOOD TESTING
8.4. RESEARCH
8.5. OTHER APPLICATIONS
9. MARKET BY END-USER
9.1. HOSPITALS
9.2. BIOPHARMACEUTICALS COMPANIES
9.3. RESEARCH ORGANIZATIONS AND ACADEMIC INSTITUTES
9.4. OTHER END-USERS
10. GEOGRAPHICAL ANALYSIS
10.1. ASIA-PACIFIC
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. ASIA-PACIFIC 3D BIOPRINTING MARKET DRIVERS
10.1.3. ASIA-PACIFIC 3D BIOPRINTING MARKET CHALLENGES
10.1.4. ASIA-PACIFIC 3D BIOPRINTING MARKET REGULATORY FRAMEWORK
10.1.5. KEY PLAYERS IN ASIA-PACIFIC 3D BIOPRINTING MARKET
10.1.6. COUNTRY ANALYSIS
10.1.6.1. CHINA
10.1.6.1.1. CHINA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.2. JAPAN
10.1.6.2.1. JAPAN 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.3. INDIA
10.1.6.3.1. INDIA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.4. SOUTH KOREA
10.1.6.4.1. SOUTH KOREA 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.5. SINGAPORE
10.1.6.5.1. SINGAPORE 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.6. THAILAND
10.1.6.6.1. THAILAND 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.7. AUSTRALIA & NEW ZEALAND
10.1.6.7.1. AUSTRALIA & NEW ZEALAND 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
10.1.6.8. REST OF ASIA-PACIFIC
10.1.6.8.1. REST OF ASIA-PACIFIC 3D BIOPRINTING MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
11.2.1. 3D BIOPRINTING SOLUTIONS
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCTS LIST
11.2.2. ADVANCED SOLUTIONS LIFE SCIENCES
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCTS LIST
11.2.3. ALLEVI
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCTS LIST
11.2.4. CELLINK
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCTS LIST
11.2.4.3. STRENGTHS & CHALLENGES
11.2.5. COLLPLANT BIOTECHNOLOGIES LTD
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCTS LIST
11.2.6. CYFUSE BIOMEDICAL KK
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCTS LIST
11.2.6.3. STRENGTHS & CHALLENGES
11.2.7. ENVISIONTEC ṁ INC
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCTS LIST
11.2.7.3. STRENGTHS & CHALLENGES
11.2.8. GESIM GMBH
11.2.8.1. COMPANY OVERVIEW
11.2.8.2. PRODUCTS LIST
11.2.8.3. STRENGTHS & CHALLENGES
11.2.9. INVENTIA LIFE SCIENCE PTY LTD
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCTS LIST
11.2.10. ORGANOVO HOLDINGS INC
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCTS LIST
11.2.10.3. STRENGTHS & CHALLENGES
11.2.11. REGEMAT 3D
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCTS LIST
11.2.11.3. STRENGTHS & CHALLENGES
11.2.12. REGENHU
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCTS LIST
11.2.12.3. STRENGTHS & CHALLENGES
11.2.13. REVOTEK CO LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCTS LIST
11.2.14. ROKIT HEALTHCARE INC
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS LIST
11.2.15. STRATASYS LTD
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCTS LIST